Although CA‐125 has limited sensitivity for detecting ovarian cancer in the early stages, it is still a useful serum marker for distinguishing between ovarian cancer and borderline ovarian tumor (BOT) [100], differentiating between benign tumors and borderline ovarian tumors [99], and discerning benign from malignant tumors [98]. Here, MUC16 is linked to benign neoplasm.